Dwarfism Clinical Trial
Official title:
Clinical and Molecular Manifestations of Human Skeletal Dysplasias and Short Stature
This study will determine the genes responsible for skeletal dysplasias (disorders of the
skeleton) and short stature and define the range and type of medical problems they cause
over time. It will investigate whether specific gene changes cause specific medical problems
in these disorders and identify the signs and symptoms upon which their diagnoses must be
based.
Individuals with short stature or with a skeletal dysplasia known or suspected to be caused
by a gene mutation (change) may be eligible for this study. Family members may also
participate. Skeletal dysplasias under study include: achondroplasia, hypochondroplasia,
achondrogenesis type II, hypochondrogenesis, Kniest dysplasia, spondyloepiphyseal
dysplasias, Stickler syndrome; Shmid and Jansen metaphyseal dysplasias; pyknodysotosis,
proximal symphalangism, brachydactyly types B C and E, Ellis van Creveld and related
disorders, metatrophic chondrodysplasias, cartilage-hair hypoplasia and disorders with a
skeletal abnormality that have not yet been defined but might be the result of a genetic
defect.
Patients will talk with two genetics specialists who will explain the study and its possible
implications for the patient and family and answer questions. The patient's medical records
will be reviewed, a personal and family history will be taken, and a physical examination
will be done. Various other procedures that may be done include drawing up to 6 tablespoons
of blood, some of which will be used for DNA (genetic) studies, X-rays, echocardiography
(ultrasound of the heart), magnetic resonance imaging (MRI), eye examination, hearing test,
sleep study, sperm analysis and skin biopsy (surgical removal of a small piece of skin done
under local anesthetic). There may be additional evaluations by specialists in rheumatology,
rehabilitation medicine and orthopedics. When the tests and examinations are completed
(after 2 to 3 days), a doctor will discuss the results with the patient. Patients whose DNA
studies show that a gene change is responsible for their disorder will meet with a genetics
nurse or counselor to review the results, express their feelings and ask any questions they
may have. Patients may be asked to return to NIH every 6 months to 2 years for continued
follow-up. Medical management will be provided primarily by the patient's own physician.
Participating family members will be interviewed by telephone about their personal and
family health history and will have a blood sample drawn for DNA testing. If a gene change
is found that is responsible for the bone disorder or growth problem in the family,
arrangements will be made for the family member to discuss the implications of the findings
with a genetics specialist.
We will investigate the clinical manifestations and molecular genetic defects of human skeletal dysplasias and generalized short stature. Families with skeletal dysplasias or short stature of known or suspected genetic basis will be enrolled. Affected individuals or individuals suspected of having a skeletal dysplasia will undergo periodic clinical assessment and genetic analyses for the purpose of: 1) definition and characterization of phenotype, 2) determination of the natural history of the disorder, and 3) genotype/phenotype correlation. Genetic linkage studies may be performed for disorders in which the genetic bases is not yet known. ;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01157793 -
A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood
|
Phase 4 | |
Completed |
NCT00001190 -
Study of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature
|
Phase 2 | |
Active, not recruiting |
NCT03255694 -
A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature
|
Phase 2 | |
Recruiting |
NCT03535415 -
A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Short Stature Children Due to Chronic Kidney Disease Before Transplantation
|
Phase 3 | |
Recruiting |
NCT03221088 -
A Study of PEG-somatropin in the Treatment of Children With Idiopathic Short Stature
|
Phase 2 | |
Completed |
NCT00234533 -
Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq
|
Phase 3 | |
Recruiting |
NCT03635580 -
Efficacy and Safety of rhGH (Jintropin®) in Pediatric Participants With ISS
|
Phase 3 | |
Completed |
NCT00001343 -
The Effects of Hormones in Growth Hormone-Treated Girls With Turner Syndrome
|
Phase 2 | |
Completed |
NCT00001536 -
Issues Surrounding Prenatal Genetic Testing for Achondroplasia
|
N/A |